October 24, 2016
- Conference Call Scheduled for
Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 96279951; or from the webcast link in the investor relations section of the company's website at: www.revance.com.
A replay of the call will be available beginning November 3,
2016 at 5:00pm PT/8:00pm ET to November 4, 2016 at
About
Revance, a
Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. More information on Revance may be found at www.revance.com.
"
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005850/en/
Investors:
jherbert@revance.com
or
abavishi@burnsmc.com
or
Trade
Media:
Nadine Tosk, (504) 453-8344
nadinepr@gmail.com
Source:
News Provided by Acquire Media